General information about ALS TDI’s Phase IIA clinical trial of TDI-132 (Gilenya, fingolimod) in ALS

February 12, 2013

The purpose of this trial and other frequently asked questions are addressed.

Sign up to receive updates about the latest ALS research, ALS TDI's work, and the community.

Related Reading

Ales for ALS™ Heads to Vegas for the 2024 Craft Brewers Conference
Read more
Join Toledo Takes on ALS Again in 2024!
Read more
Sano Genetics Joins ALS TDI Town Hall to Discuss Genetic Testing for ALS
Read more

Learn more about our team, what we're working on in the lab, and our amazing community by following us on social media!

Author:

Talk with Us

Whether you have questions about research, resources, clinical trials, or just want to connect and have a conversation, we want to hear from you.

Learn more about our team, what we're working on in the lab, and our amazing community by following us on social media!

Sign up to receive updates about the latest ALS research, ALS TDI's work, and the community